Anhedonia has received special attention in diagnosing and treating psychiatric disorders for decades. Anhedonia is a transdiagnostic concept (
1) that has been included in the official classification since the DSM-III and is one of the essential criteria for major depressive disorder (MDD) in the DSM-5 (
2) as well as in the research domain criteria approach system (
3,
4). The concept is defined as “the loss of the ability to experience pleasure” (
5). Anhedonia is a hallmark of psychiatric disorders, including MDD and schizophrenia, personality disorders, eating disorders, anxiety disorders, and organic diseases (
6). Furthermore, 50 to 78 percent of MDD was associated with the anhedonia symptom in the UK (
7). In previous research, anhedonia was the only dimension that could predict a longer recovery time and poor treatment outcome (
6). Therefore, the concept is significant as a specific prognostic feature and therapeutic target for people with recurrent depression.
In recent years, the assessment of anhedonia has received renewed attention. Updated conceptualization suggests that anhedonia includes desire, effort, subjective pleasure, and cognitive components (e.g., the capability to predict and anticipate award) (
1,
8,
9). Also, research shows that approximately 45% of the studies that measured anhedonia did not define the concept (
10). These dilemmas in anhedonia conceptualization have made the measurement of anhedonia difficult and inaccurate, leading to a lack of good tools to address various aspects of the “pleasure response” (
8).
The most widely used tools for evaluating anhedonia include the Snaith-Hamilton Pleasure Scale (SHAPS) (
11), the Faust-Clark Pleasure Capacity Scale (FCPS) (
12), the Renewal Scale, Chapman Physical Anhedonia (CPAS), and Chapman Social Anhedonia Scale (CSAS) (
13,
14). Although most of these tools have been used in previous research, they have some limitations. These scales are sometimes time-consuming, culturally biased, and outdated. They may also have poor differential validity and the fact that existing tools must fully reflect all components of reward processing to adequately assess anhedonia. As a result, the lack of any of these dimensions can underestimate the evaluation of the pleasure experience, so that this evaluation can cover the various components of the structure (
5,
15).
Finally, Rizvi (
15) developed a Dimensional Anhedonia Rating Scale (DARS), unlike previous scales that focus on the specific components of anhedonia (
9,
16-
18). It has an integrated approach to evaluating anhedonia and evaluates various characteristics, such as interest, motivation, virtual activities, and enjoyable consumption across different areas, namely entertainment, food and drink, social activities, and sensory experiences. All four dimensions in the DARS are essential and must be answered thoroughly. Confirming this point, Lambert suggests that DARS is the only scale that has so far been evaluated validly in an MDD (major depression disorder) sample that assesses the various aspects of anhedonia (
1).
The DARS questionnaire was designed to investigate as many aspects of reward processing as possible where anhedonia may be based on irregularities (
8). DARS considers interest, effort, motivation, and satisfaction across hedonic domains (
15). The persons completing the questionnaire provide examples of their favorites in the four subscales: hobby (hobby/pastimes), food/drinks, spending time with friends (social activities), and sensory experiences (
15). DARS has more predictive power than the best pre-existing alternative questionnaire (SHAPS) and helps diagnose the subtypes of depression (such as recurrent depression) (
9). The questionnaire requires respondents to express some of the activities they perceive as satisfying (e.g., gardening and playing the guitar under hobbies/past times), which may include some of the issues related to age differences in what people might find rewarding (adolescents vs. adults vs. elderly) (
5,
15,
19).
Previous studies have reported excellent internal consistency of DARS and a significant correlation between DARS and the severity of depression (
9,
15,
20,
21). It also supports the idea that anhedonia is an overlapping but distinct structure with depression (
5). Also, it explains the higher depression variance than SHAPS. Clinically determining MDD subtypes and the relevance of such clinical aspects to neurobiology is crucial for improving treatment selection strategies (
22).